Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Bile be gone

With $23M, Lumena looks to advance liver disease compound through Phase II

Bile be gone

Lumena Pharmaceuticals Inc. is looking to advance its lead compound LUM001 through three Phase II cholestatic liver disease trials with funds from its $23 million series A.

President and CEO Mike Grey said the

Read the full 350 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers